New Ray Medicine International Holding Limited reported no changes to its share capital structure for the month ended 30 June 2026, according to its latest monthly return filed with Hong Kong Exchanges and Clearing Limited on 2 July 2026.

• Authorised share capital stayed at HKD 150.00 million, representing 15.00 billion ordinary shares with a par value of HKD 0.01 each.

• Issued share capital remained flat at 200.62 million ordinary shares. The company held no treasury shares and recorded no share repurchases, cancellations or new issuances during the month.

• Public-float compliance was confirmed, with at least 25% of issued shares held by the public as required under Main Board Rule 13.32B.

• Under the Share Option Scheme adopted on 25 October 2013, 12.82 million share options were outstanding at month-end. No options were exercised, lapsed or cancelled, and no proceeds were raised from option exercises.

• The issuer reported no outstanding warrants, convertible securities, or other agreements that could dilute current shareholders.

Overall, New Ray Medicine’s capital base and share structure were unchanged in June 2026, providing continuity for existing shareholders while leaving significant authorised but unissued shares available for future corporate actions.